TreatmentUnited StatesEuropeLe Moir · Seoul
Ultherapy Prime600-line full-face reference
$2,500–4,500Public-market range
€1,800–3,500(≈ $2,050–3,990)Public-market range
₩2.50M(≈ $1,700)Clinic reference · before VATBelow both listed ranges
Thermage FLX600-shot full-face reference
$3,500–5,500Public-market range
€2,500–4,500(≈ $2,850–5,125)Public-market range
₩2.50M(≈ $1,700)Clinic reference · before VATBelow both listed ranges
Rejuran Healer4 cc full-face reference
$1,000–2,000Public-market range
€800–1,500(≈ $910–1,710)Public-market range
₩600K(≈ $408)Clinic reference · before VATBelow both listed ranges
XERFFull-face references; shot protocols vary
$1,500–2,500NYC and Los Angeles public references
€2,340–2,925(≈ $2,665–3,330)London £2,000–2,500 converted
₩1.99M(≈ $1,354)600-shot member-package component · before VATLower member reference; confirm standalone quote
Re2O · Rituo1 vial · mixed to 5 cc · full face
Not routinely availableNo standardized US aesthetic price
No comparable public rangeProduct access and regulation differ
₩600K(≈ $408)Clinic reference · before VATNo like-for-like savings claim
Juvelook1-vial full-face reference
Limited public pricingAvailability and protocols vary
€690(≈ $786)London £590 one-vial price converted
₩600K(≈ $408)1 vial · mixed to 8 cc · before VATBelow the listed London reference
Xeomin12-unit single wrinkle-area reference
$96–216Derived from $8–18 per unit
€175–350(≈ $199–399)Public one-area prices; dose may differ
₩70K(≈ $48)12U · one wrinkle area · before VATBelow the listed overseas references
Belotero filler1 cc reference; treatment area varies
$475+Public per-syringe reference
€220–350(≈ $251–399)Public 1 ml clinic prices
₩300K(≈ $204)Belotero · 1 cc · before VATBelow the listed overseas references
VALUE CHECKUltherapy Prime, Thermage FLX, Rejuran, Xeomin 12U and Belotero 1 cc remain below the listed overseas references after conversion. Juvelook is below the London one-vial example. XERF uses a member-package component—not a guaranteed standalone price—and Re2O is not given a savings claim because direct overseas access and pricing are not comparable.